Part I: Milestones in personalised medicine--imatinib

Lancet Oncol. 2008 Jun;9(6):600. doi: 10.1016/S1470-2045(08)70152-9.
No abstract available

Publication types

  • Historical Article

MeSH terms

  • Antineoplastic Agents / history*
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • History, 20th Century
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / history*
  • Patient Selection
  • Piperazines / history*
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / history*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / history*
  • Pyrimidines / therapeutic use
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate